This Fund Could Aid the Health of More than a Portfolio

Jim Woods

The PureFunds ETFx HealthTech ETF (Nasdaq: IMED) stands at an interesting crossroads between the field of medicine itself and the technology used to advance medical knowledge and treatment in new and exciting ways.

This intersection between medicine and technology has been dubbed “HealthTech.” Medicine continuously is driven forward by the application of new technology and data solutions to devices and procedures. “HealthTech” has made things like 3D-printed prosthetics, robot-assisted surgery and telemedicine popular buzzwords in the medical field.

One advantage that HealthTech has over other, more stagnant areas of the market and the medical field is its growth prospects. Obamacare initiatives and biotech, the drug manufacturing arm of the medical field, face an uncertain future under President Trump’s proposed policies, but there is always going to be demand for better and more advanced technology to keep the medical field on the cutting edge. According to Fortune, venture funding into HealthTech jumped 200% over five years (2010-2014) and the industry was valued at $72 trillion in 2015 in the United States alone.

Despite this, HealthTech has been slow to get investor attention, probably because of the tendancy to invest in more traditional medical plays, such as biotech. PureFunds, the manager/sponsor of the popular cybersecurity ETF HACK, saw that there was no ETF assigned to the HealthTech arena and launched IMED just last year for that exact purpose.

Created on August 31, 2016, IMED is tied to the ETFx HealthTech Index and tracks companies around the world that use technology to design and deliver health care solutions. The fund avoids pharmaceutical companies, which are currently on uncertain footing, and instead targets medical infomatics, instruments and devices.

Exclusive  Daily Data Flow: Apple Distracts from S&P; Jobs Numbers Improving; Yen Slumps

According to Andrew Chanin, CEO of PureFunds, IMED has less than 40% overlap with any other health care ETF currently available. The fund does not pay a dividend at present, has an expense ratio of 0.75% and only about $4.4 million in net assets, partly as a result of being less than a year old. In terms of performance, IMED has done well since its inception and is up close to 24% year to date.

A company must have a market capitalization of at least $500 million to be included in the index, and it contained 22 foreign investments as of June 2016. IMED itself holds 48 positions currently and is approximately 75% in health care and 25% in technology. Its top five holdings are: Teladoc, Inc. (TDOC), 3.12%; Medidata Solutions, Inc. (MDSO), 3.00%; CompuGroup Medical SE, 2.78%; athenahealth, Inc. (ATHN), 2.77%; and Veeva Systems, Inc., Class A (VEEV), 2.67%

In short, HealthTech has the potential to be long-term player in the medical and health care field. If the intersection between medicine and technology sounds like an interesting investment strategy, then the PureFunds ETFx HealthTech ETF (Nasdaq: IMED) could be a solid choice.

As always, I am happy to answer any of your questions about ETFs, so do not hesitate to send me an email. You just may see your question answered in a future ETF Talk.

Like This Article?
Now Get Jim's FREE Special Report:
The Top 11 Dividend ETFs to
Buy Right Now

Get up to 5X the yields of traditional income plays.

Get Access to the Report, 100% FREE


img
previous article

Ladies and gentlemen, halftime is over. I hope you enjoyed your Fourth of July respite, because now it’s time to get back on the field and start playing the second half of 2017 in the markets. Before we attempt to determine where this market is going for the rest of the year, it’s probably a good idea to look back and see where we’ve been. That’s certainly the philosophy of one of my favorite Founding Fathers, Patrick Henry, who once famously said, “I know of no way of judging th

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen publishes 5 different investment newsletter advisories, including the award-winning Forecasts & Strategies, which has beaten the market over the last 15 years.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays. Bryan's four newsletter and trading services include:

Product Details

LEARN MORE HERE

Nicholas Vardy

A Stanford and Harvard Law graduate, Nicholas Vardy scours over 40 different global markets every day to uncover new profit opportunities for subscribers. His 3 advisories and trading services include:

Product Details

LEARN MORE HERE

Jim Woods

A 20-plus-year veteran of the markets, Jim Woods has varied experience as a broker, hedge fund trader, financial writer, author and newsletter editor.

Product Details

LEARN MORE HERE

Bob Carlson

In Bob's monthly newsletter, Retirement Watch, he provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE

DividendYieldHunter.com

Editor Tim McPartland has published Dividend Yield Hunter since 2006. His web site features three model dividend portfolios along with timely income investing alerts.

Product Details

LEARN MORE HERE